7. AI is in the hands of HCPs. How will pharma adapt?

7. AI is in the hands of HCPs. How will pharma adapt?

Pharma commercial strategy looks different in the age of AI—and goes beyond mainstream uses such as generative AI. Read the latest news and musing from Viz.ai on why pharma can’t sleep on AI at the point of care.


?? The Latest

??? Our CEO and Co-founder, Dr Chris Mansi was named on the TIME100 AI List of the World’s Most Influential People in Artificial Intelligence.

?? How will pharma adapt to the changing healthcare landscape now that AI is in the palm of our HCP’s hands?


?? Viz News

??Cleerly a match — Viz.ai and Cleerly are partnering to deliver critical insights to cardiovascular care teams.

?? The results are in from a 美国加州大学圣迭戈分校 study on Viz CONNECT —?the study determined Viz.ai's impact in driving patient diagnosis, faster HCP decision-making, and enhanced patient care!

?? Viz LVO has demonstrated a 14% increase in patient transfers treated with endovascular thrombectomy, reducing futile transfers and driving substantial cost savings in stroke care!

?? Lucky number 3?? The Galien Foundation has nominated Viz HCM in the category of 'Best Digital Health Solution,' making it the third year a Viz product has been nominated.

?? We are proud to announce that Viz.ai One?? is a finalist in the 2024 Pharmaceutical Executive APEX Awards—judged entirely by healthcare professionals and the patients they treat.

Viz.ai ???? ALCMI. We're partnering with Addario Lung Cancer Medical Institute (ALCMI) to improve lung cancer ?? outcomes in patients by focusing on early detection ??.?


?? Vizion

Cleerly in action —?read the Skeptical Cardiologist's (Anthony Pearson, M.D., F.A.C.C) take on a study utilizing CCTA with Cleerly. According to the author, CCTA/Cleerly has the potential to change (some might say transform) how we detect and prevent ASCVD.

?? Lung cancer screening took center stage at the recent World Conference on Lung Cancer (WCLC), read why in the Imaging Wire.

According to research conducted by McKinsey & Co., “by the end of this year, the United States is expected to have a shortage of up to 64,000 physicians.” This data underscores the need for healthcare organizations to take urgent action. Enter Clinical AI, a solution addressing patient care and workflow challenges the Viz.ai platform — enabling HCPs to focus on what’s important, patients.


??Physician Perspective?

Jack Manley, MD , Head of New Markets & Growth at Viz.ai, participated as a panelist on Fierce Pharma’s Tailored Connections: The Power of Personalization in HCP Marketing. Couldn’t make it to Philly for #DPE2024, catch up on-demand here.

Embedding AI tools into an HCP's workflow helps them make more efficient and better care decisions

Moderator: Nandini Nayar Global Digital Health and Innovation Lead, Sanofi

Panelists:

Kamya Elawadhi SVP- Platform & Corporate Strategy, Doceree

Lori Holland-Hancock Director Channel Strategy & Engagement Team, Oncology, 默克

Jack Manley, MD Head of New Markets and Growth, Viz.ai

Gunjan Aggarwal Executive Director | Head - Data Strategy and Marketing Data Solutions, 诺华

Silvia Schneiders Filippi Director of Marketing, HALOZYME, INC


??? Events

????? HLTH 2024 | October 20-23 | Las Vegas

Join us at HLTH to learn how we harness the power of AI to guide more patients to the right diagnosis and the right treatment, faster. Get the conversation started today. #HLTHUSA


?? Reuters Customer Engagement 2024 | October 22-23 | Philadelphia

Join Tom Krohn, VP, Global Pharma Commercial Lead for a panel discussion with pharma leaders, Amir Golan - Novartis, Bryan Hancsin - Genmab, Christina Kotsi - Bayer, and Prem Schoff - Novo Nordisk. The event will cover how to Pinpoint Omnichannel reach and impact and leverage new channels to strengthen your customer journey on October 22 @ 4:50 pm ET. #REcustomerUSA?


About Viz.ai

As healthcare’s leading AI platform with 13 FDA-cleared algorithms, Viz.ai is used in over 1,700 hospitals and health systems to analyze medical imaging, EHR data, and more, accelerating diagnosis and treatment. In partnership with pharmaceutical and medical device companies, Viz.ai develops customized solutions for treatable diseases. These solutions are integrated into HCP clinical workflows, empowering HCPs with real-time insights so they can treat more patients and swiftly take the next best clinical action, enhancing adherence to clinical guidelines and advancing patient care. For more information visit Viz.ai/life-sciences.


??? Contributors

Get in touch with Tom Krohn and Sherie Zhou

548 Market St., # 21826, San Francisco, CA 94104

Between issues, keep current with the latest updates from Viz.ai by following us on LinkedIn and by subscribing to the exclusive email version of Innovizion, sent bi-monthly directly to your inbox from Team Viz.

要查看或添加评论,请登录

社区洞察

其他会员也浏览了